TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02387606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily.
Study: NCT05327231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 every 21 days a cycle.
Study: NCT00995774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic therapy
Description: 12 sessions of robot therapy for arm and hand function
Study: NCT02387606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
Study: NCT03772132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mutation and signal pathway activation status analysis Drug: FORFIRINOX
Description: Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
Study: NCT03066921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic packet
Description: Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
Study: NCT05213182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Women of Today
Description: Adolescent mothers engaged in the development and implementation of the intervention which also involved key community stakeholders to address stigma related to mental illness and adolescent motherhood. Community health workers and peer educators in the intervention arm were recruited and trained on co-facilitating peer support groups. The intervention arm (n=104 adolescent mothers) participated in the peer support groups and completed sociodemographic, base-, mid-, and end-line surveys. The control arm (n=79 adolescent mothers) completed sociodemographic, base-, mid- and end-line surveys. Peer support groups (12 groups with 6-12 participants in each group) met in-person twice a month and completed 12 peer-group sessions from May-August 2019 addressing participant identified topics such as depression. WhatsApp Messenger was used for training and implementation support. Key community stakeholders met to discuss project progress and recommendations to improve adolescent mothers' health.
Study: NCT04307056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: The surgical approach can be open or laparoscopic. The procedure begins with lymph node dissection for the intermediate risk groups (PSA \> 10 ng/mL and/or presence of grade 4 Gleason score). Total prostatectomy includes removal of the seminal vesicles. It can preserve 1 or 2 neurovascular bundles, depending on the cancer stage and/or the choice expressed by the patient. The vesicourethral suture is either a running or interrupted suture, and there is drainage by a bladder catheter for at least 5 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound (HIFU) Treatment
Description: The treatment with High Intensity Focused Ultrasound (HIFU) evaluated in this study will be delivered by 2 types of medical devices currently available on the market, Ablatherm® and Focal One®. They are both computer-controlled and provided with an endo-rectal probe with integrated ultrasound, enabling planning and the monitoring of treatment of localized prostate cancer in realtime.
Study: NCT02315014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whey protein
Description: whey protein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo.
Study: NCT02443909

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Intrarenal Surgery
Description: Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
Study: NCT01826266

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PER977, Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PER977, Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PER977, Placebo
Study: NCT00995774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional functional training
Description: 12 sessions of conventional therapy for the arm and hand from a physical therapist

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic therapy
Description: 12 sessions of robot therapy for arm and hand function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional functional training
Description: 12 sessions of conventional therapy for the arm and hand from a physical therapist
Study: NCT03069326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
Study: NCT04131348

Intervention type: PROCEDURE
Group type: OTHER
Intervention: botulinum toxin type A
Description: From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
Study: NCT03899389

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma samples collection
Description: Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
Study: NCT03899389

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma samples collection
Description: Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma samples collection
Description: Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
Study: NCT01250782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: 0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: 100 mL of physiological serum indistinguishable from active comparator
Study: NCT02374944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hardware removal
Description: Comparison of implant retention vs. scheduled implant removal in skeletally mature patients with previously operatively treated Lisfranc injuries requiring screw and/or plate fixation.
Study: NCT00366444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium (XP21L)
Description: 25 mg every 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every 6 hours
Study: NCT05734144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The intraoperative ERCP has been performed immediately before LC
Description: combination approach has been used to improve patient compliance and shorten hospital stays. The intraoperative ERCP has been performed immediately before Laparoscopic Cholecystectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: POES followed by LC
Description: Treatment in two stages, which combines a preoperative ES followed by LC (sequential treatment).
Study: NCT02850276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Study: NCT03001726

Intervention type: PROCEDURE
Intervention: Gastrectomy
Description: In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.

Intervention type: DRUG
Intervention: oxaliplatin
Description: oxaliplatin 100 mg/m2

Intervention type: DRUG
Intervention: oxaliplatin
Description: oxaliplatin 100 mg/m2

Intervention type: DRUG
Intervention: S1
Description: S1 40mg/m2
Study: NCT01638585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: urokinase
Description: daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
Study: NCT03001726

Intervention type: DRUG
Intervention: S1
Description: S1 40mg/m2

Intervention type: DRUG
Intervention: Docetaxel
Description: docetaxel 40 mg/m2

Intervention type: DRUG
Intervention: Docetaxel
Description: docetaxel 40 mg/m2
Study: NCT03636685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with pemetrexed and carboplatin, phase I
Description: Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin
Study: NCT00753025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration, injection of cells
Description: Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration , injection of isolated CD 133+ cells
Description: arm CD133 receives injection of isolated CD 133+ cells
Study: NCT03636685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with paclitaxel and carboplatin, phase I
Description: Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with pemetrexed and carboplatin, phase II
Description: Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib combined with paclitaxel and carboplatin, phase II
Description: Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
Study: NCT00753025

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow aspiration, injection of saline
Description: arm placebo receives injection of saline
Study: NCT03841773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablets
Description: Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Study: NCT03062644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR308
Description: two times daily; Mode of Administration:oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR308
Description: two times daily; Mode of Administration:oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR308
Description: two times daily; Mode of Administration:oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: four times daily; Mode of Administration:oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR308
Description: two times daily; Mode of Administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MR308
Description: given four times daily to maintain the blind; Mode of Administration:oral
Study: NCT03137524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Held Fan Therapy
Description: Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
Study: NCT00820014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
Study: NCT00362297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir
Description: 800 mg orally three times daily for 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: 500 mg orally once daily for 7 weeks
Study: NCT01408862

Intervention type: OTHER
Intervention: venous puncture
Description: Blood for in vitro studies will be drawn
Study: NCT01228084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological study
Description: Correlative studies
Study: NCT00806611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol Block
Description: Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Block
Description: Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
Study: NCT01078974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
Study: NCT04228666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Four IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory data will be collected prior to first infusion; follow-up data will be compared against baseline according to the following schedule: safety laboratory tests follow-up on weeks 4, 8, 13, 26, and 52; inflammation and amyloid markers follow-up on weeks 13 and 52; MMSE and ADCS-ADL follow-up on weeks 13, 19, 26, 33, 40, 46 and 52; Altoida NMI follow-up will occur weekly from week 0 to week 52; CDR follow-up will occur weeks 4, 10, 13, 19, 26, 33, 40, 46 and 52; C-SSRS follow-up will occur on weeks 4, 10, 26, and 52; Amyloid PET imaging follow-up occurs week 26 and 52;
Study: NCT01804504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
Study: NCT02181335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Respimat® Budesonide low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Respimat® Budesonide high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler® Budesonide
Study: NCT01276366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breast feeding
Description: Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
Study: NCT02181335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02681120

Intervention type: PROCEDURE
Intervention: MRI
Study: NCT02604524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop Control
Description: Subjects will use the CLC during 5 nights/6 days at a ski camp.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensor Augmented Pump Therapy
Description: Subjects using their personal pumps with study CGM.
Study: NCT03893136

Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
Study: NCT03763474

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Euglyca application
Description: 'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
Study: NCT00508131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Cows Milk
Description: 400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
Study: NCT03893136

Intervention type: DRUG
Intervention: Leflunomide
Description: The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
Study: NCT03034421

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bed rest
Description: Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
Study: NCT01394523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5%
Study: NCT01276366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supplemental breast milk
Description: In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
Study: NCT01394523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.25% or 0.5%
Study: NCT02988921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI and CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ratiotherapy
Study: NCT00508131

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole Cows Milk
Description: 400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
Study: NCT05863169

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fNIRS-Neurofeedback
Description: Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fNIRS-Neurofeedback
Description: Neurofeedback of cortical oxygenation in 4 channels (2 left hemisphere, 2 right hemisphere); 8 training sessions, each session includes 2 feedback blocks (2\*12 activation/deactivation trials) and one transfer block (8 activation/deactivation trials)
Study: NCT03377738

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spirometry
Description: All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.